William Knebel, Pharm.D., Ph.D.

President, Quantitative Sciences

Bill joined MetrumRG in 2004, where he was appointed President of Strategic Modeling & Simulation in 2016 after serving most recently as Principal Scientist II and Group Leader of the Pharmacology Modeling & Simulation Team. Bill has worked extensively in applying mathematical modeling and simulation techniques to optimize drug development across both academic and industrial settings. In his 17 years at MetrumRG, Bill has taken a leadership role in strengthening our team’s capabilities and has been a champion of applying high-performance cloud computing environments to facilitate problem solving in drug development.

Recent publications by this scientist

Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion

April 10, 2021

Riccobene TA, Carrothers TJ, Knebel W, Raber S, Chan PLS. Clin Pharmacol Drug Dev. 2021 Apr;10(4):420-427. doi: 10.1002/cpdd.907.

Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.

November 13, 2020

Kang J, Eudy-Byrne RJ, Mondick J, Knebel W, Jayadeva G, Liesenfeld KH. Br J Clin Pharmacol. 2020 Nov;86(11):2274-2285. doi: 10.1111/bcp.14330.

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients with Tenosynovial Giant Cell Tumor (TGCT) or Other Solid Tumors

November 18, 2019

Ophelia Yin, Jia Kang, William Knebel, Hamim Zahir, Michiel van de Sande, William D. Tap, Hans Gelderblom, Silvia Stacchiotti, Jon Greenberg, Dale Shuster, Andrew J. Wagner

Poster presented at 2019 American Conference on Pharmacometrics (ACoP10) in Orlando, FL. 21 October 2019.

Download PDF